These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

966 related articles for article (PubMed ID: 28734176)

  • 1. Cancer immunotherapy: moving forward with peptide T cell vaccines.
    Kumai T; Fan A; Harabuchi Y; Celis E
    Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Old concepts, new tricks: How peptide vaccines are reshaping cancer immunotherapy?
    Liu Q; Wu P; Lei J; Bai P; Zhong P; Yang M; Wei P
    Int J Biol Macromol; 2024 Nov; 279(Pt 4):135541. PubMed ID: 39270889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
    Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-based vaccines for cancer therapy.
    Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
    Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
    Yang QY; Yang JD; Wang YS
    Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse immunoediting: When immunity is edited by antigen.
    Merlo A; Dalla Santa S; Dolcetti R; Zanovello P; Rosato A
    Immunol Lett; 2016 Jul; 175():16-20. PubMed ID: 27131431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.
    Saxena M; Bhardwaj N
    Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition.
    Sultan H; Kumai T; Fesenkova VI; Fan AE; Wu J; Cho HI; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2018 May; 6(5):617-627. PubMed ID: 29483127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Composite peptide-based vaccines for cancer immunotherapy (Review).
    Yang J; Zhang Q; Li K; Yin H; Zheng JN
    Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.
    Overwijk WW
    Curr Opin Immunol; 2017 Aug; 47():103-109. PubMed ID: 28806603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Neoantigens.
    Schumacher TN; Scheper W; Kvistborg P
    Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines targeting helper T cells for cancer immunotherapy.
    Melssen M; Slingluff CL
    Curr Opin Immunol; 2017 Aug; 47():85-92. PubMed ID: 28755541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
    Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
    Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
    Barrow AD; Colonna M
    Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and future prospects of peptide-based cancer vaccines.
    Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
    Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for immunotherapy of acute myeloid leukemia using γδ T cells.
    Halim L; Parente-Pereira AC; Maher J
    Immunotherapy; 2017 Jan; 9(2):111-114. PubMed ID: 28128710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 49.